Gene expression–based assays for cancers of unknown primary (CUP)
Customize your policy alerts
Sign up for Capital Bluecross Policy MP 2.245 alerts
Get alerted when Policy MP 2.245 changes without checking for updates manually.
Monitor payer policy activity
This policy governs coverage of gene expression and comprehensive genomic profiling tests used to identify the tissue/site of origin for cancers of unknown primary and to guide treatment selection. It applies to Capital BlueCross-administered programs and products as described in the policy.
Policy marked as RETIRED with effective date 7/1/2026.
Gene expression and/or comprehensive genomic profiling is considered investigational to evaluate site of origin of a tumor of unknown primary, to distinguish primary from metastatic tumor, or to guide treatment selection.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.